Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT03062657
NCT03062657TerminatedNot Applicable

An Investigation of the Metal Concentration in Patients Implanted With the PRESTIGE LP™ Cervical Disc at Two Contiguous Levels in the Cervical Spine

Medtronic Spinal and Biologics8 sites in 1 country25 target enrollmentStarted: June 6, 2018Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Terminated
Sponsor
Enrollment
25
Locations
8
Primary Endpoint
Concentrations of Titanium, Vanadium, and Aluminum in the Blood Serum
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

This clinical study will assess the metal concentrations present in the blood serum of patients who receive surgical treatment with the PRESTIGE LP™ Cervical Disc at two contiguous cervical levels from C3-C7. The information obtained from this clinical investigation will be used to support the post market surveillance for a PMA supplement for the PRESTIGE LP™ Cervical Disc implanted at two contiguous levels.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •A patient must meet all of the following inclusion criteria to participate in this study:
  • •Has cervical degenerative disc disease at two (2) contiguous cervical levels (from C3 to C7) requiring surgical treatment and involving intractable radiculopathy, myelopathy or both;
  • •Has a herniated disc and/or osteophyte formation at each level to be treated that is producing symptomatic nerve root and/or spinal cord compression. The condition is documented by patient history (e.g., neck and/or arm pain, functional deficit and /or neurological deficit), and the requirement for surgical treatment is evidenced by radiographic studies (e.g., CT, MRI, x-rays, etc.);
  • •Has been unresponsive to non-operative treatment for at least six weeks or has the presence of progressive symptoms or signs of nerve root/spinal cord compression in the face of continued non-operative therapy;
  • •Has no previous surgical intervention at the involved levels or any other planned/staged surgical procedure at the involved levels;
  • •Has preoperative neck pain score ≥ 8 based on the preoperative Neck and Arm Pain Questionnaire;
  • •Must be at least 18 years of age and be skeletally mature at the time of surgery;
  • •If a female of childbearing potential, patient is non-pregnant, non-nursing, and agrees not to become pregnant during the study period;
  • •Is willing to comply with the study plan and sign the Patient Informed Consent Form.

Exclusion Criteria

  • •A patient will be excluded from participating in this study for any of the following reasons:
  • •Has a cervical spine condition other than symptomatic cervical degenerative disease requiring surgical treatment at the involved levels;
  • •Has documented or diagnosed cervical instability relative to contiguous segments at either level, defined by dynamic (flexion/extension) radiographs showing:
  • •Sagittal plane translation > 3.5 mm, or
  • •Sagittal plane angulation > 20°
  • •Has more than two cervical levels requiring surgical treatment;
  • •Has severe pathology of the facet joints of the involved vertebral bodies;
  • •Has had previous surgical intervention at either one or both of the involved levels;
  • •Has been previously diagnosed with osteopenia or osteomalacia;
  • •Has any of the following that may be associated with a diagnosis of osteoporosis (If "Yes" to any of the below risk factors, a DEXA Scan will be required to determine eligibility.):
  • •. Postmenopausal non-Black female over 60 years of age who weighs less than 140 pounds.
  • •Postmenopausal female who has sustained a non-traumatic hip, spine or wrist fracture.
  • •Male over the age of
  • •Male over the age of 60 who has sustained a non-traumatic hip or spine fracture.
  • •If the level of BMD is a T score of -3.5 or lower (i.e., -3.6, -3.7, etc.) or a T score of -2.5 or lower (i.e., -2.6, -2.7 etc.) with vertebral crush fracture, then the patient is excluded from the study
  • •Has presence of spinal metastases;
  • •Has overt or active bacterial infection, either local or systemic;
  • •Has chronic or acute renal failure or prior history of renal disease;
  • •Has a documented allergy or intolerance to titanium, or a titanium alloy;
  • •Is mentally incompetent. (If questionable, obtain psychiatric consult);
  • •Is a prisoner;
  • •Is pregnant;
  • •Has received drugs that may interfere with bone metabolism within two weeks prior to the planned date of spinal surgery (e.g., steroids or methotrexate), excluding routine perioperative anti-inflammatory drugs;
  • •Has history of an endocrine or metabolic disorder known to affect osteogenesis (e.g., Paget's Disease, renal osteodystrophy, Ehlers-Danlos Syndrome, or osteogenesis imperfecta);
  • •Has a condition that requires postoperative medications that interfere with the stability of the implant, such as steroids. (This does not include low-dose aspirin for prophylactic anticoagulation and routine perioperative anti-inflammatory drugs.);
  • •Has received treatment with an investigational therapy within 28 days prior to implantation surgery or such treatment is planned during the 16 weeks following implantation.
  • •Is currently taking or has had chronic usage of certain prescription medications (e.g., Cloxacillin, an antibiotic used for prophylaxis against surgical infections, and/or Clotrimazole).

Outcomes

Primary Outcomes

Concentrations of Titanium, Vanadium, and Aluminum in the Blood Serum

Time Frame: Preoperative, 6 weeks, and 12 months

The concentrations of Titanium, Vanadium, and Aluminum at different time points will be summarized using mean and standard deviation. One participant did not receive metal concentration analysis at baseline, therefore the baseline number of participants for these measures N = 24.

Secondary Outcomes

  • Number of Participants Who Achieved Overall Success(3, 6, and 12 months)
  • Neck Pain and Arm Pain(Preoperative, 3, 6, and 12 months)
  • Number of Participants Who Underwent Secondary Surgery at Index Level(3, 6, and 12 months)
  • Number of Participants Who Achieved NDI Success(3, 6, and 12 months)
  • Number of Participants Who Achieved Neurological Success(3, 6, and 12 months)

Investigators

Sponsor
Medtronic Spinal and Biologics
Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (8)

Loading locations...

Similar Trials

Terminated
Not Applicable
Whole Blood Metal Ion Concentrations in Metal-on-metal Total Hip Arthroplasty and Hip ResurfacingOsteoarthritis, Hip
NCT04585022Hvidovre University Hospital75
Not yet recruiting
Not Applicable
Metal-ions in Patients With the PEEK HD Coupling Mechanism of the KneeMutarsModular Universal Tumor And Revision SystemMetal-ionsTumor ProsthesisMegaprosthesisPEEK-HD Coupling MechanismKnee Endoprosthesis
NCT05893602Leiden University Medical Center30
Completed
Not Applicable
Determination of Metal Ion Serum Levels and Cytokines in Total Hip ReplacementHip Replacement Arthroplasty
NCT01394744Ludwig-Maximilians - University of Munich30
Completed
Not Applicable
Metal Ions in Ceramic on Metal Total Hip ArthroplastyRheumatoid ArthritisOsteoarthritisAvascular NecrosisDevelopmental Dysplasia of the Hip
NCT01437124Hussain Kazi83
Enrolling By Invitation
Not Applicable
Metal Ion Concentrations After Total Knee ArthroplastyArthroplasty, Replacement, KneeTotal Knee ReplacementBlood Metal Ion Concentration
NCT06447922Mayo Clinic60